1jp5
From Proteopedia
Line 1: | Line 1: | ||
[[Image:1jp5.jpg|left|200px]] | [[Image:1jp5.jpg|left|200px]] | ||
- | + | <!-- | |
- | + | The line below this paragraph, containing "STRUCTURE_1jp5", creates the "Structure Box" on the page. | |
- | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
- | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
- | + | or leave the SCENE parameter empty for the default display. | |
- | + | --> | |
- | + | {{STRUCTURE_1jp5| PDB=1jp5 | SCENE= }} | |
- | + | ||
- | + | ||
- | }} | + | |
'''Crystal structure of the single-chain Fv fragment 1696 in complex with the epitope peptide corresponding to N-terminus of HIV-1 protease''' | '''Crystal structure of the single-chain Fv fragment 1696 in complex with the epitope peptide corresponding to N-terminus of HIV-1 protease''' | ||
Line 19: | Line 16: | ||
==About this Structure== | ==About this Structure== | ||
- | + | Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1JP5 OCA]. | |
==Reference== | ==Reference== | ||
Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal antibody., Rezacova P, Lescar J, Brynda J, Fabry M, Horejsi M, Sedlacek J, Bentley GA, Structure. 2001 Oct;9(10):887-95. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/11591344 11591344] | Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal antibody., Rezacova P, Lescar J, Brynda J, Fabry M, Horejsi M, Sedlacek J, Bentley GA, Structure. 2001 Oct;9(10):887-95. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/11591344 11591344] | ||
- | [[Category: Mus musculus]] | ||
- | [[Category: Protein complex]] | ||
[[Category: Bentley, G A.]] | [[Category: Bentley, G A.]] | ||
[[Category: Brynda, J.]] | [[Category: Brynda, J.]] | ||
Line 32: | Line 27: | ||
[[Category: Rezacova, P.]] | [[Category: Rezacova, P.]] | ||
[[Category: Sedlacek, J.]] | [[Category: Sedlacek, J.]] | ||
- | [[Category: | + | [[Category: Antibody-antigen complex]] |
- | [[Category: | + | [[Category: Hiv pr inhibiting antibody]] |
- | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 21:32:17 2008'' | |
- | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + |
Revision as of 18:32, 2 May 2008
Crystal structure of the single-chain Fv fragment 1696 in complex with the epitope peptide corresponding to N-terminus of HIV-1 protease
Overview
BACKGROUND: Since the demonstration that the protease of the human immunodeficiency virus (HIV Pr) is essential in the viral life cycle, this enzyme has become one of the primary targets for antiviral drug design. The murine monoclonal antibody 1696 (mAb1696), produced by immunization with the HIV-1 protease, inhibits the catalytic activity of the enzyme of both the HIV-1 and HIV-2 isolates with inhibition constants in the low nanomolar range. The antibody cross-reacts with peptides that include the N terminus of the enzyme, a region that is highly conserved in sequence among different viral strains and that, furthermore, is crucial for homodimerization to the active enzymatic form. RESULTS: We report here the crystal structure at 2.7 A resolution of a recombinant single-chain Fv fragment of mAb1696 as a complex with a cross-reactive peptide of the HIV-1 protease. The antibody-antigen interactions observed in this complex provide a structural basis for understanding the origin of the broad reactivity of mAb-1696 for the HIV-1 and HIV-2 proteases and their respective N-terminal peptides. CONCLUSION: A possible mechanism of HIV-protease inhibition by mAb1696 is proposed that could help the design of inhibitors aimed at binding inactive monomeric species.
About this Structure
Full crystallographic information is available from OCA.
Reference
Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal antibody., Rezacova P, Lescar J, Brynda J, Fabry M, Horejsi M, Sedlacek J, Bentley GA, Structure. 2001 Oct;9(10):887-95. PMID:11591344 Page seeded by OCA on Fri May 2 21:32:17 2008